参考文献 References
[1] Kent L N, Leone G. The broken cycle: E2F dysfunction in cancer[J]. Nature Reviews Cancer, 2019, 19(6): 326-338.
[2] 王舒莞,汪琢.E2F家族对肌肉骨骼系统发育和相关疾病的影响[J].生物化学与生物物理进展,2025,52(04):915-929.
[3] 李飞飞, 王韵, 顾冀海, 等. E2F家族转录因子在肿瘤发生中的作用[J].遗传, 2023, 45(7): 580-592.
[4] Lammens T, Li J, Leone G, et al. Atypical E2Fs: new players in the E2F transcription factor family[J]. Trends Cell Biol, 2009, 19(3): 111-118.
[5] Westendorp B, Mokry M, Groot Koerkamp M J, et al. E2F7 represses a network of oscillating cell cycle genes to control S-phase progression[J]. Nucleic Acids Research, 2012, 40(8): 3511-3523.
[6] Lyu Y, Zhang J, Li L, et al. Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report[J]. Bioscience Reports, 2020, 40(2): BSR20193212.
[7] Eoh KJ, Kim HJ, Lee JW, et al. E2F8 induces cell proliferation and invasion through the epithelial-mesenchymal transition and notch signaling pathways in ovarian cancer[J]. Int J Mol Sci, 2020, 21(16): 5813.
[8] Park JP, Lee JW, López-Giráldez F, et al. E2F8 as a Novel Therapeutic Target for Lung Cancer[J]. J Natl Cancer Inst, 2015, 107(9): djv151.
[9] Ye L, Guo L, He Z, et al. Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition[J]. Oncotarget. 2016;7(17):23757-23771.
[10] Lee S, Park YR, Kim SH, et al. Geraniol suppresses prostate cancer growth through down-regulation of E2F8[J]. Cancer medicine. 2016;5(10):2899-2908.
[11] Yao H, Lu F, Shao Y. The E2F family as potential biomarkers and therapeutic targets in colon cancer [J]. Peer J, 2020, 8:e8562.
[12] Shimada Y, Kuninaga S, Ariyoshi M, et al. E2F8 promotes hepatic steatosis through FABP3 expression in diet-induced obesity in zebrafish[J]. Nutr Metab (Lond). 2015;12:17.
[13] Logan N, Graham A, Zhao X, et al. E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7[J]. Oncogene, 2005, 24(31): 5000-5004.
[14] Yuan R, Liu Q, Seceren HA, et al. Cyclin F-dependent degradation of E2F7 is critical for DNA repair and G₂-phase progression [J]. The EMBO Journal, 2019, 38(20): e101430.
[15] Christensen J. Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription[J].Nucleic Acids Research. 2005;33:5458-70.
[16] Lv Y, Xiao J, Liu J,et al. E2F8 is a Potential Therapeutic Target for Hepatocellular Carcinoma[J]. J Cancer. 2017 Apr 9;8(7):1205-1213.
[17] 刘宗超，李哲轩，张阳，等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志，2021,7(2):1-14.
[18] Zhang S, Zhou K, Luo X, et al. The polyploid state plays a tumor-suppressive role in the liver[J]. Developmental Cell, 2018, 44(4): 447-459.
[19] Wilkinson PD, Delgado ER, Alencastro GA, et al.The polyploid state restricts hepatocyte proliferation and liver regeneration in mice[J]. Hepatology, 2019, 69(3): 1242–1258.
[20] Pandit SK, Westendorp B, Nantasanti S, et al. E2F8 is essential for polyploidization in mammalian cells[J]. Nat Cell Biol, 2012, 14(11): 1181–1191.
[21] Kent LN, Rakijas JB, Pandit SK, et al. E2f8 mediates tumor suppression in postnatal liver development[J]. J Clin Invest, 2016, 126(8): 2955–2969.
[22] Lyu Y, Zhang J, Li L, et al. Carcinogenesis effects of E2F transcription factor 8 (E2F8) in hepatocellular carcinoma outcomes: an integrated bioinformatic report[J]. Bioscience Reports, 2020, 40(2): BSR20193212.
[23] Deng Q, Wang Q, Zong WY, et al. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation[J]. Cancer Res, 2010, 70(2): 782–791.
[24] Rinella ME,Neuschwander-Tetri BA,Siddiqui MS,et al.AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023,77(5):1797-1835.
[25] 中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志，2018, 26(3):195-203.
[26] Lou TW,Yang RX,Fan JG.The global burden of fatty liver disease:the major impact of China[J].Hepatobiliary Surg Nutr,2024,13(1):119-123.
[27] Shimada Y, Kuninaga S, Ariyoshi M,et al. E2F8 promotes hepatic steatosis through FABP3 expression in diet-induced obesity in zebrafish[J]. Nutr Metab (Lond). 2015 May 20;12:17.
[28] Suwa A, Yoshino M, Kurama T,et al.. Glucose regulates RMI1 expression through the E2F pathways in adipose cells[J]. Endocrine. 2011;40:56-61.
[29] Suwa A, Yoshino M, Yamazaki C, et al. RMI1 deficiency in mice protects from diet and genetic-induced obesity[J]. FEBS J. 2010;277:677-86.
[30] Cigrovski BM, Virovic-Jukic L, Bilic-cucic I, et al. Post-transplant diabetes mellitus and preexisting liver disease-a bidirectional relationship affecting treatment and management[J]. World Journal of Gastroenterol,2020, 26(21):2740-2757.
[31] Shan L, Liu Z N, Ci L L, et al. Research progress on the anti-hepatic fibrosis action and mechanism of natural products[J]. International Immunopharmacol,2019, 75: 105765.
[32] Weijts BG, Bakker WJ, Cornelissen PW, et al. E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1[J]. EMBO J. 2012;31:3871-84.
[33] Li xq, Cao zr, Deng m, ,et al. E2F8-TPX2 axis regulates glycolysis and angiogenesis to promote progression and reduce chemosensitivity of liver cancer[J]. Cytotechnology. 2024 Dec;76(6):817-832.
[34] Shenoda B, Boselli J. Vascular syndromes in liver cirrhosis[J].Clinical Journal of Gastroenterology,2019, 12(5):387-97.
[35] Li J,Wang H,Cao F,et al.A bioinformatics analysis for diagnostic roles of the E2F family in esophageal cancer[J].J Gastrointest Oncol,2022,13(5):2115-2131.
[36] Chang H,Song J,Wu J,et al.E2F transcription factor 8 promotes cell proliferation via CCND1/p21 in esophageal squamous cell carcinoma[J].Onco Targets Ther,2018,11: 8165- 8173.
[37] Lu T,Wang R,Cai H,et al.Long non-coding RNA DLEU2 promotes the progression of esophageal cancer through miR-30e-5p/E2F7 axis[J].Biomed Pharmacother,2020, 123: 109650.
[38] Zhang S,Sun K,Zheng R,et al. Cancer incidence and mortality in China,2015[J]. J Natl Cancer Cent,2020,1(1): 2-11.
[39] Zhang F,Guo C,Cao X,et al.Gastric cancer cell-derived extracellular vesicles elevate E2F7 expression and activate the MAPK/ERK signaling to promote peritoneal metastasis through the delivery of SNHG12[J].Cell Death Discov, 2022 ,8(1):164.
[40] Li S,Yang X,Li W,et al.Comprehensive analysis of E2F family members in human gastric cancer[J].Front Oncol, 2021,11:625257.
[41] 徐颖.E2F7、E-cadherin、Vimentin在胃癌组织中的表达及临床意义研究[D].遵义医科大学，2023.
[42] 胰腺癌诊疗指南(2022年版)[J].临床肝胆病杂志,2022, 38(05):1006-1030.
[43] 孙惠昕，贾海晗，王婉莹，等.胰腺癌流行现状和影响因素的研究[J].医学信息，2022,35(11):47-50.
[44] Luo L,Zhang G,Wu T,et al.Prognostic value of E2F transcription factor expression in pancreatic adenocarcino-ma[J]. Med Sci Monit,2021,27:933443.
[45] 中国结直肠癌诊疗规范（2020年版）[J].中国实用外科杂志,2020,40(06):601-625.
[46] Yao H,Lu F,Shao Y.The E2F family as potential biomarkers and therapeutic targets in colon cancer[J].Peer J,2020, 8:e8562.
[47] Yan PY,Zhang Xa.Knockdown of E2F8 suppresses cell proliferation in colon cancer cells by modulating the NF-κB pathway[J].Annals of Clinical and Laboratory Science, 2019,49(4):474-480.
[48] Zhang Z,Li J,Huang Y,et al.Upregulated miR-1258 regulates cell cycle and inhibits cell proliferation by directly targeting E2F8 in CRC[J].Cell Prolif,2018,51(6): e12505.